IV Ofatumumab Reduces Relapses in MS, But Not Better Than Kesimpta
An intravenous (into-the-vein) formulation of ofatumumab ā a disease-modifying therapy for multiple sclerosis (MS) sold under the brand name Kesimpta ā resulted in a 63% reduction in relapse rates among MS patients, with about 60% remaining relapse-free over the first year of treatment, a recent study in…